Gopal G Krishna, MD
Nephrology · Salinas
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 8 carriers
- Offices
- 2
Offices
2 locations · Central Coast Nephrology Medical Corporation · 11 clinicians in this group
Hospitals listed: 052892 · 552724 · Community Hospital of the Monterey Peninsula · Hazel Hawkins Memorial Hospital · Natividad Medical Center · Salinas Valley Health Medical Center. That is not proof they admit you there this week.
Plans that list them
28 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Krishna’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A36123 · Current
Licensed to practise in California · since 1980 · expires 2028-08-31 · Andhra University, Andhra Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Natividad Medical CenterSalinas, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Natividad Medical CenterPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.316, Oct 2024 – Sep 2025
- Salinas Valley Health Medical CenterSalinas, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Salinas Valley Memorial Healthcare SystemPatients rate it 4 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.247, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Natividad Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.316 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.98 (0 to 2.04) · 332 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.18 (0.76 to 1.6) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 165.77 (109.76 to 221.78) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 80 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 110 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.5 · 34 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 609 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.48) · 2,445 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 2,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.36 (2.03 to 6.7) · 564 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 79 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.08 (0.44 to 3.71) · 555 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.67 (1.19 to 20.15) · 87 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.92 (0.71 to 9.12) · 79 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.24) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.07 (0.12 to 2.02) · 1,742 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.462 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 62 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.4 · 93 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -7.3 · 121 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.9) · 162 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.7 to 1.5) · 72 cases | No different | Jan 2024 – Dec 2024 |
What patients said (966 patients answered, 55% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Salinas Valley Health Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.247 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.32 (0.34 to 2.3) · 1,159 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.68 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.42 (143.23 to 253.6) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 112 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 203 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 536 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.1 · 239 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 2,377 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 7,593 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.43) · 7,999 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.97 (1.83 to 6.1) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.7 (0.16 to 3.24) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.87 to 3.76) · 1,325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.78 (3.73 to 15.83) · 461 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.23 (1.52 to 8.95) · 453 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 279 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.48 (0 to 1.11) · 6,011 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.487 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.082 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.432 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.373 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 197 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 491 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 224 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8 · 660 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 569 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 485 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.9 (4.2 to 8.4) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 86 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 197 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 489 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,383 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$856,721
Medicare paid this office $856,721 for 622 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Dialysis services, 4 or more physician visits per month (20 years or older) | 69 | $170,748 | $285 |
| Injection, denosumab, 1 mg | 32 | $38,578 | None |
| Home dialysis services per month (20 years or older) | 19 | $37,012 | $230 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 222 | $32,168 | $64 |
| Injection, romosozumab-aqqg, 1 mg | 11 | $26,981 | None |
See all 25 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 69 | $170,748 | $285 |
| Injection, denosumab, 1 mg | 32 | $38,578 | None |
| Home dialysis services per month (20 years or older) | 19 | $37,012 | $230 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 222 | $32,168 | $64 |
| Injection, romosozumab-aqqg, 1 mg | 11 | $26,981 | None |
| Return visit (30+ min) | 116 | $17,872 | $56 |
| Hemodialysis procedure with physician evaluation | 145 | $15,367 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $12,777 | $139 |
| Dialysis procedure including 1 evaluation | 30 | $7,529 | $70 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 21 | $6,966 | $240 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 39 | $4,236 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $3,276 | $96 |
| Short return visit (20+ min) | 42 | $3,158 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 37 | $3,071 | $53 |
| Long return visit (40+ min) | 17 | $1,812 | $91 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 91 | $1,810 | $12 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 16 | $1,766 | $0 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $1,637 | $109 |
| Injection of drug or substance under skin or into muscle | 62 | $1,585 | $12 |
| Influenza vaccine split virus, preservative free | 14 | $1,136 | $81 |
| Insertion of needle into vein for collection of blood sample | 58 | $969 | $9 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $761 | $40 |
| Kidney function blood test panel | 50 | $757 | $9 |
| Administration of chemotherapy into vein, each additional hour | 12 | $730 | $24 |
| Administration of influenza virus vaccine | 18 | $611 | $34 |
Who their Medicare patients are
622 Original Medicare patients in 2024. Average age 72 · Under 65 21% · 85 and older 12% · Women 51% · Also on Medicaid 53% · Health risk score 5.10. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 70% · Heart failure 47% · Coronary heart disease 43% · Atrial fibrillation 32% · Depression 28% · COPD 23% · Stroke 13% · Dementia 11% · Cancer 10%.
The office billed $1,761,922, Medicare allowed $1,091,641 and paid $856,721; for 31,733 services of 67 kinds; $527,990 of it was for drugs given in the office and $328,732 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 622 | 31,733 | 72 | 5.10 | $1,761,922 | $856,721 |
| 2023 | 693 | 33,803 | 72 | 4.65 | $1,638,371 | $788,575 |
| 2022 | 678 | 28,096 | 72 | 4.16 | $998,616 | $476,184 |
| 2021 | 707 | 41,978 | 72 | 4.04 | $1,556,208 | $769,407 |
| 2020 | 739 | 42,134 | 71 | 4.48 | $1,236,265 | $549,130 |
| 2019 | 702 | 28,593 | 71 | 4.68 | $1,258,015 | $551,719 |
| 2018 | 759 | 40,910 | 71 | 4.37 | $1,525,104 | $676,678 |
| 2017 | 860 | 43,390 | 71 | 4.17 | $1,569,712 | $692,568 |
| 2016 | 835 | 35,319 | 71 | 3.94 | $1,477,394 | $651,563 |
| 2015 | 760 | 27,182 | 71 | 4.04 | $1,046,238 | $465,756 |
| 2014 | 733 | 23,963 | 71 | 3.89 | $979,763 | $446,702 |
| 2013 | 755 | 13,672 | 71 | 3.95 | $782,077 | $365,383 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 31 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 58 | $135,372 | $297 |
| Injection, denosumab, 1 mg | 48 | $55,094 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 255 | $41,036 | $66 |
| Injection, inclisiran, 1 mg | 11 | $29,072 | None |
| Home dialysis services per month (20 years or older) | 21 | $28,895 | $247 |
| Hemodialysis procedure with physician evaluation | 158 | $20,601 | $60 |
| Return visit (30+ min) | 131 | $16,873 | $53 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $12,651 | $145 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 30 | $12,364 | $247 |
| Dialysis procedure including 1 evaluation | 24 | $7,236 | $72 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 60 | $6,883 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $3,490 | $100 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 34 | $3,242 | $55 |
| Short return visit (20+ min) | 44 | $3,224 | $58 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13 | $2,889 | $0 |
| New patient visit (45+ min) | 23 | $2,850 | $124 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $2,818 | $113 |
| Long return visit (40+ min) | 23 | $2,319 | $86 |
| Influenza vaccine split virus, preservative free | 25 | $1,798 | $72 |
| Injection of drug or substance under skin or into muscle | 86 | $1,788 | $12 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 28 | $1,403 | $41 |
| Insertion of needle into vein for collection of blood sample | 84 | $1,394 | $8 |
| Kidney function blood test panel | 69 | $1,144 | $9 |
| Complete ultrasound scan behind abdominal cavity | 11 | $1,080 | $98 |
| Administration of chemotherapy into vein, each additional hour | 16 | $931 | $24 |
| Administration of influenza virus vaccine | 30 | $832 | $28 |
| Injection of drug or substance into vein | 11 | $448 | $32 |
| Blood test, comprehensive group of blood chemicals | 23 | $248 | $10 |
| Manual urinalysis test with examination using microscope, non-automated | 16 | $63 | $4 |
| Red blood cell concentration measurement | 16 | $63 | $2 |
| Blood count, hemoglobin | 16 | $63 | $2 |
2022: 26 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 73 | $150,630 | $309 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 231 | $32,705 | $61 |
| Home dialysis services per month (20 years or older) | 12 | $24,362 | $251 |
| Injection, denosumab, 1 mg | 21 | $23,790 | None |
| Hemodialysis procedure with physician evaluation | 142 | $18,839 | $62 |
| Return visit (30+ min) | 125 | $17,523 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $9,824 | $169 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 80 | $9,373 | $116 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 57 | $8,235 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 22 | $7,688 | $1 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 18 | $6,695 | $258 |
| Short return visit (20+ min) | 80 | $5,807 | $53 |
| Dialysis procedure including 1 evaluation | 26 | $5,753 | $75 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,058 | $87 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 40 | $2,850 | $58 |
| Long return visit (40+ min) | 15 | $2,592 | $136 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 49 | $2,513 | $33 |
| Influenza vaccine split virus, preservative free | 31 | $2,047 | $66 |
| Injection of drug or substance under skin or into muscle | 82 | $1,847 | $12 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $1,798 | $50 |
| New patient visit (45+ min) | 12 | $1,768 | $147 |
| Kidney function blood test panel | 111 | $1,596 | $9 |
| Complete ultrasound scan behind abdominal cavity | 12 | $1,210 | $101 |
| Administration of influenza virus vaccine | 34 | $951 | $28 |
| Insertion of needle into vein for collection of blood sample | 129 | $638 | $3 |
| Blood count, hemoglobin | 43 | $134 | $2 |
2021: 30 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 61 | $168,320 | $305 |
| Return visit (30+ min) | 130 | $43,258 | $106 |
| Injection, denosumab, 1 mg | 32 | $35,075 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 237 | $30,043 | $61 |
| Home dialysis services per month (20 years or older) | 12 | $24,228 | $247 |
| Hemodialysis procedure with physician evaluation | 128 | $16,761 | $62 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 34 | $14,852 | $1 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $12,209 | $170 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 42 | $10,153 | None |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 24 | $8,423 | $255 |
| Short return visit (20+ min) | 69 | $7,289 | $74 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 54 | $6,651 | $115 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 54 | $5,699 | $63 |
| Dialysis procedure including 1 evaluation | 23 | $3,503 | $75 |
| New patient visit (45+ min) | 21 | $3,057 | $146 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $2,895 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $2,888 | $88 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $2,878 | $103 |
| Long return visit (40+ min) | 17 | $2,332 | $130 |
| Injection of drug or substance under skin or into muscle | 77 | $2,244 | $12 |
| Complete ultrasound scan behind abdominal cavity | 21 | $2,234 | $102 |
| Kidney function blood test panel | 146 | $1,946 | $9 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 35 | $1,440 | $33 |
| Influenza vaccine split virus, preservative free | 20 | $1,240 | $62 |
| Administration of chemotherapy into vein, each additional hour | 12 | $966 | $27 |
| Insertion of needle into vein for collection of blood sample | 165 | $774 | $3 |
| Administration of influenza virus vaccine | 29 | $525 | $18 |
| Blood test, comprehensive group of blood chemicals | 24 | $264 | $11 |
| Blood count, hemoglobin | 47 | $194 | $2 |
| Hemoglobin a1c level | 12 | $117 | $10 |
2020: 28 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 98 | $146,868 | $244 |
| Return visit (30+ min) | 147 | $33,869 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 232 | $30,843 | $62 |
| Home dialysis services per month (20 years or older) | 18 | $21,715 | $197 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 31 | $17,688 | $1 |
| Injection, denosumab, 1 mg | 15 | $17,631 | None |
| Hemodialysis procedure with physician evaluation | 148 | $17,286 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $15,708 | $173 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 49 | $14,114 | None |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 29 | $9,740 | $207 |
| Short return visit (20+ min) | 94 | $7,888 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 56 | $6,567 | $108 |
| Dialysis procedure including 1 evaluation | 24 | $5,570 | $75 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 51 | $5,097 | $61 |
| Long return visit (40+ min) | 19 | $3,077 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $3,062 | $90 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $2,735 | $94 |
| Injection of drug or substance under skin or into muscle | 74 | $2,596 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $2,150 | $126 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 44 | $1,650 | $32 |
| Kidney function blood test panel | 122 | $1,411 | $9 |
| Influenza vaccine split virus, preservative free | 23 | $1,362 | $59 |
| Administration of chemotherapy into vein, each additional hour | 12 | $837 | $27 |
| Administration of influenza virus vaccine | 31 | $555 | $18 |
| Insertion of needle into vein for collection of blood sample | 134 | $553 | $3 |
| Short return visit | 13 | $475 | $34 |
| Blood count, hemoglobin | 49 | $191 | $2 |
| Blood test, comprehensive group of blood chemicals | 14 | $158 | $11 |
2019: 28 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 110 | $162,317 | $232 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 74 | $34,734 | $200 |
| Return visit (30+ min) | 142 | $32,107 | $85 |
| Home dialysis services per month (20 years or older) | 16 | $26,167 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 213 | $25,041 | $60 |
| Injection, denosumab, 1 mg | 22 | $22,514 | None |
| Hemodialysis procedure with physician evaluation | 125 | $15,093 | $61 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 51 | $13,762 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 21 | $10,338 | $1 |
| Short return visit (20+ min) | 112 | $9,292 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $8,177 | $164 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $6,259 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 41 | $4,279 | $63 |
| Dialysis procedure including 1 evaluation | 15 | $3,259 | $72 |
| Dialysis services, 1 physician visit per month (20 years or older) | 13 | $2,945 | $134 |
| Injection of drug or substance under skin or into muscle | 82 | $2,539 | $14 |
| Long return visit (40+ min) | 15 | $2,033 | $120 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $1,983 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $1,908 | $87 |
| New patient visit (45+ min) | 12 | $1,499 | $125 |
| Kidney function blood test panel | 107 | $1,335 | $9 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 33 | $902 | $27 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 22 | $788 | $32 |
| Short return visit | 19 | $608 | $29 |
| Administration of influenza virus vaccine | 33 | $588 | $18 |
| Administration of chemotherapy into vein, each additional hour | 11 | $584 | $27 |
| Insertion of needle into vein for collection of blood sample | 115 | $459 | $3 |
| Blood count, hemoglobin | 42 | $168 | $3 |
2018: 27 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 119 | $213,269 | $229 |
| Injection, denosumab, 1 mg | 88 | $83,187 | None |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 84 | $39,281 | $191 |
| Return visit (30+ min) | 145 | $32,876 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 215 | $30,752 | $58 |
| Home dialysis services per month (20 years or older) | 17 | $25,363 | $186 |
| Hemodialysis procedure with physician evaluation | 164 | $21,557 | $59 |
| Injection, ferric carboxymaltose, 1 mg | 18 | $16,154 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $15,365 | $163 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 43 | $12,269 | None |
| Short return visit (20+ min) | 116 | $8,885 | $54 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 37 | $4,212 | $108 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $4,084 | $1 |
| Dialysis procedure including 1 evaluation | 21 | $4,073 | $70 |
| Injection of drug or substance under skin or into muscle | 136 | $3,787 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 36 | $3,305 | $60 |
| Short return visit | 86 | $2,638 | $28 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $2,270 | $84 |
| Dialysis services, 1 physician visit per month (20 years or older) | 12 | $2,126 | $152 |
| Long return visit (40+ min) | 11 | $1,730 | $124 |
| Kidney function blood test panel | 118 | $1,661 | $11 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 35 | $1,571 | $30 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,175 | $59 |
| Insertion of needle into vein for collection of blood sample | 128 | $506 | $3 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 17 | $401 | $24 |
| Administration of influenza virus vaccine | 17 | $390 | $23 |
| Blood count, hemoglobin | 40 | $155 | $3 |
2017: 27 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 113 | $162,308 | $222 |
| Injection, denosumab, 1 mg | 118 | $118,490 | None |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 91 | $45,887 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 288 | $45,837 | $56 |
| Return visit (30+ min) | 154 | $33,701 | $80 |
| Hemodialysis procedure with physician evaluation | 181 | $27,480 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 130 | $22,745 | $158 |
| Home dialysis services per month (20 years or older) | 18 | $21,160 | $179 |
| Injection, ferric carboxymaltose, 1 mg | 15 | $14,624 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 48 | $11,741 | None |
| Short return visit (20+ min) | 112 | $8,787 | $53 |
| Injection of drug or substance under skin or into muscle | 167 | $5,715 | $21 |
| Short return visit | 114 | $4,091 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 42 | $4,049 | $56 |
| Dialysis procedure including 1 evaluation | 21 | $3,800 | $68 |
| Dialysis services, 1 physician visit per month (20 years or older) | 18 | $3,540 | $136 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,537 | $111 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 48 | $2,196 | $30 |
| Kidney function blood test panel | 134 | $1,961 | $12 |
| Long return visit (40+ min) | 15 | $1,776 | $111 |
| Dialysis services, per day, less than full month service (20 years or older) | 17 | $1,511 | $6 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,449 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,418 | $79 |
| Administration of influenza virus vaccine | 31 | $836 | $26 |
| Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage | 31 | $582 | $18 |
| Insertion of needle into vein for collection of blood sample | 143 | $526 | $3 |
| Blood count, hemoglobin | 37 | $178 | $3 |
2016: 28 services
| Dialysis services, 2-3 physician visits per month (20 years or older) | 95 | $106,146 | $194 |
| Injection, denosumab, 1 mg | 121 | $96,534 | None |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 74 | $85,239 | $223 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 256 | $46,735 | $58 |
| Return visit (30+ min) | 159 | $34,259 | $83 |
| Home dialysis services per month (20 years or older) | 17 | $26,990 | $189 |
| Hemodialysis procedure with physician evaluation | 164 | $25,672 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 136 | $23,941 | $162 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 44 | $16,607 | None |
| Short return visit (20+ min) | 125 | $10,518 | $52 |
| Dialysis services, 1 physician visit per month (20 years or older) | 29 | $7,331 | $150 |
| Injection of drug or substance under skin or into muscle | 168 | $6,164 | $20 |
| Dialysis procedure including 1 evaluation | 26 | $5,932 | $70 |
| Short return visit | 113 | $3,443 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 25 | $3,157 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,922 | $108 |
| Kidney function blood test panel | 164 | $2,531 | $11 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 50 | $2,292 | $32 |
| New patient visit (45+ min) | 16 | $2,003 | $125 |
| Dialysis services, per day, less than full month service (20 years or older) | 20 | $1,889 | $6 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $1,778 | $85 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,398 | $87 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,122 | $56 |
| Insertion of needle into vein for collection of blood sample | 177 | $692 | $3 |
| Administration of influenza virus vaccine | 18 | $478 | $27 |
| Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage | 18 | $294 | $16 |
| Blood count, hemoglobin | 49 | $260 | $3 |
| Manual urinalysis test with examination using microscope, non-automated | 16 | $68 | $4 |
2015: 30 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 83 | $147,591 | $224 |
| Injection, denosumab, 1 mg | 71 | $58,180 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 268 | $43,447 | $58 |
| Return visit (30+ min) | 140 | $29,099 | $83 |
| Hemodialysis procedure with physician evaluation | 167 | $23,363 | $59 |
| Home dialysis services per month (20 years or older) | 16 | $20,879 | $186 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 115 | $20,312 | $159 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 49 | $15,153 | $192 |
| Short return visit (20+ min) | 148 | $13,352 | $53 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 40 | $10,591 | None |
| Injection of drug or substance under skin or into muscle | 114 | $4,107 | $20 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 71 | $3,837 | $31 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,367 | $112 |
| Dialysis procedure including 1 evaluation | 16 | $3,046 | $71 |
| Kidney function blood test panel | 130 | $2,545 | $11 |
| Short return visit | 65 | $2,429 | $33 |
| New patient visit (45+ min) | 16 | $2,119 | $132 |
| Long return visit (40+ min) | 18 | $1,911 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $1,862 | $85 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $1,788 | $56 |
| Dialysis services, per day, less than full month service (20 years or older) | 12 | $1,269 | $6 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,228 | $88 |
| Complete ultrasound scan behind abdominal cavity | 12 | $1,147 | $96 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,014 | $60 |
| Insertion of needle into vein for collection of blood sample | 150 | $732 | $3 |
| Administration of influenza virus vaccine | 26 | $691 | $26 |
| Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage | 26 | $354 | $13 |
| Blood count, hemoglobin | 55 | $327 | $3 |
| Blood test, comprehensive group of blood chemicals | 13 | $173 | $13 |
| Manual urinalysis test with examination using microscope, non-automated | 18 | $76 | $4 |
2014: 31 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 84 | $154,923 | $228 |
| Injection, denosumab, 1 mg | 51 | $38,443 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 230 | $33,725 | $58 |
| Return visit (30+ min) | 159 | $32,963 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 129 | $22,689 | $159 |
| Hemodialysis procedure with physician evaluation | 145 | $22,111 | $58 |
| Home dialysis services per month (20 years or older) | 15 | $21,994 | $185 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 45 | $14,590 | $192 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 54 | $11,773 | None |
| Short return visit (20+ min) | 119 | $9,965 | $54 |
| Injection of drug or substance under skin or into muscle | 109 | $4,219 | $20 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $4,054 | $110 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $3,998 | $1 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 81 | $3,755 | $31 |
| Dialysis procedure including 1 evaluation | 19 | $3,524 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $2,767 | $84 |
| Long return visit (40+ min) | 17 | $2,405 | $109 |
| Kidney function blood test panel | 117 | $2,151 | $11 |
| Short return visit | 49 | $1,793 | $34 |
| New patient visit (45+ min) | 13 | $1,687 | $130 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,648 | $87 |
| Hospital discharge day management, 30 minutes or less | 28 | $1,646 | $59 |
| Dialysis services, per day, less than full month service (20 years or older) | 15 | $1,555 | $6 |
| Complete ultrasound scan behind abdominal cavity | 13 | $1,436 | $103 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $701 | $50 |
| Injection of drug or substance into vein | 11 | $686 | $46 |
| Insertion of needle into vein for collection of blood sample | 140 | $681 | $3 |
| Administration of influenza virus vaccine | 24 | $636 | $24 |
| Blood count, hemoglobin | 67 | $351 | $3 |
| Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage | 24 | $334 | $13 |
| Manual urinalysis test with examination using microscope, non-automated | 18 | $76 | $4 |
2013: 28 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 101 | $110,388 | $224 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 292 | $48,974 | $55 |
| Return visit (30+ min) | 194 | $37,618 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 180 | $31,978 | $158 |
| Hemodialysis procedure with physician evaluation | 161 | $26,718 | $57 |
| Home dialysis services per month (20 years or older) | 20 | $22,673 | $187 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 45 | $15,875 | None |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 34 | $9,638 | $189 |
| Short return visit (20+ min) | 97 | $7,131 | $60 |
| Dialysis procedure including 1 evaluation | 18 | $5,083 | $69 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 95 | $4,599 | $30 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12 | $3,775 | $1 |
| Injection of drug or substance under skin or into muscle | 51 | $3,377 | $21 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $2,837 | $105 |
| Long return visit (40+ min) | 19 | $2,470 | $107 |
| Complete ultrasound scan behind abdominal cavity | 20 | $2,404 | $114 |
| New patient visit (45+ min) | 19 | $2,021 | $106 |
| Dialysis services, per day, less than full month service (20 years or older) | 14 | $1,864 | $6 |
| Kidney function blood test panel | 104 | $1,851 | $12 |
| Hospital discharge day management, more than 30 minutes | 21 | $1,805 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,463 | $81 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $954 | $64 |
| Hospital discharge day management, 30 minutes or less | 11 | $689 | $57 |
| Administration of influenza virus vaccine | 20 | $568 | $27 |
| Insertion of needle into vein for collection of blood sample | 114 | $546 | $3 |
| Blood count, hemoglobin | 52 | $304 | $3 |
| Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage | 17 | $207 | $12 |
| Manual urinalysis test with examination using microscope, non-automated | 17 | $77 | $4 |
Medicaid work
$168,733 in 2024
Medicaid paid $168,733 for 1,485 billed services this clinician did in 2024, up to 74 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 633 | $120,425 |
| End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older | 155 | $22,786 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 447 | $15,005 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 211 | $7,919 |
| 1ST HOSP IP/OBS HIGH 75 | 27 | $1,809 |
| Return visit (30+ min) | 12 | $790 |
| 2024 | 1,485 | 6 | 74 | $168,733 |
| 2023 | 1,779 | 6 | 51 | $161,714 |
| 2022 | 1,752 | 6 | 64 | $156,939 |
| 2021 | 1,633 | 4 | 57 | $159,785 |
| 2020 | 1,497 | 5 | 73 | $139,078 |
| 2019 | 1,579 | 7 | 82 | $156,301 |
| 2018 | 1,874 | 5 | 99 | $174,201 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 553 | $104,157 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 649 | $24,028 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 381 | $14,336 |
| End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older | 70 | $11,435 |
| Return visit (30+ min) | 96 | $5,758 |
| 1ST HOSP IP/OBS HIGH 75 | 30 | $2,000 |
2022
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 591 | $114,764 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 639 | $20,901 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 360 | $13,063 |
| Return visit (30+ min) | 131 | $7,608 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 16 | $310 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $293 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 628 | $124,331 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 565 | $17,730 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 321 | $12,692 |
| Return visit (30+ min) | 119 | $5,032 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 682 | $113,980 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 470 | $12,509 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 232 | $8,023 |
| Return visit (30+ min) | 101 | $3,207 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 12 | $1,360 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 799 | $122,817 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 138 | $13,423 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 415 | $13,068 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 186 | $6,595 |
| Short return visit (20+ min) | 17 | $241 |
| Return visit (30+ min) | 12 | $113 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 12 | $43 |
2018
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 950 | $130,380 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 471 | $16,511 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 149 | $14,843 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 277 | $11,751 |
| Return visit (30+ min) | 27 | $716 |
Drugs they prescribed that Part D paid
$385,283
Pharmacies billed $385,283 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,037) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
1,716 generic and 321 brand-name prescriptions · $385,283 in drug cost · 21 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 73 | $91,067 | $1,247 |
| Velphoro | 20 | $53,697 | $2,685 |
| Veltassa | 35 | $37,942 | $1,084 |
| Lokelma | 45 | $26,637 | $592 |
| Farxiga | 18 | $24,055 | $1,336 |
See all 45 drugs
| Jardiance | 73 | $91,067 | $1,247 |
| Velphoro | 20 | $53,697 | $2,685 |
| Veltassa | 35 | $37,942 | $1,084 |
| Lokelma | 45 | $26,637 | $592 |
| Farxiga | 18 | $24,055 | $1,336 |
| Rayaldee | 12 | $21,511 | $1,793 |
| Kerendia | 12 | $20,011 | $1,668 |
| Sevelamer Carbonate | 120 | $15,972 | $133 |
| Calcium Acetate | 27 | $4,346 | $161 |
| Mycophenolate Mofetil | 17 | $3,193 | $188 |
| Clonidine | 16 | $3,119 | $195 |
| Bumetanide | 36 | $2,007 | $56 |
| Losartan | 170 | $1,874 | $11 |
| Metoprolol | 82 | $1,857 | $23 |
| Prosol | 11 | $1,629 | $148 |
| Amlodipine Besylate | 181 | $1,510 | $8 |
| Doxazosin Mesylate | 94 | $1,442 | $15 |
| Valsartan | 21 | $1,054 | $50 |
| Telmisartan | 23 | $998 | $43 |
| Chlorthalidone | 34 | $987 | $29 |
| Minoxidil | 25 | $960 | $38 |
| Atorvastatin | 103 | $891 | $9 |
| Furosemide | 92 | $835 | $9 |
| Lactulose | 42 | $772 | $18 |
| Omeprazole | 52 | $595 | $11 |
| Carvedilol | 54 | $522 | $10 |
| Potassium Chloride | 23 | $496 | $22 |
| Albuterol Sulfate Hfa | 12 | $492 | $41 |
| Pantoprazole | 38 | $395 | $10 |
| Torsemide | 40 | $382 | $10 |
| Cephalexin | 19 | $279 | $15 |
| Famotidine | 14 | $264 | $19 |
| Allopurinol | 36 | $263 | $7 |
| Gabapentin | 19 | $252 | $13 |
| Ramipril | 23 | $235 | $10 |
| Nystatin | 15 | $235 | $16 |
| Spironolactone | 15 | $216 | $14 |
| Prednisone | 14 | $172 | $12 |
| Glipizide | 19 | $160 | $8 |
| Hydralazine | 13 | $153 | $12 |
| Calcitriol | 21 | $148 | $7 |
| Metoprolol | 19 | $138 | $7 |
| Ondansetron | 15 | $137 | $9 |
| Finasteride | 12 | $65 | $5 |
| Tamsulosin | 12 | $53 | $4 |
Year by year
| 2024 | 2,037 | 207 | 0% (0) | 16% | $385,283 |
| 2023 | 2,361 | 200 | 0% (0) | 17% | $509,246 |
| 2022 | 2,772 | 210 | 0% (0) | None | $478,321 |
| 2021 | 2,904 | 214 | None | 17% | $472,299 |
| 2020 | 2,818 | 221 | None | 18% | $461,465 |
| 2019 | 3,265 | 242 | None | 17% | $519,366 |
| 2018 | 4,025 | 239 | 0% (14) | 16% | $590,738 |
| 2017 | 4,676 | 255 | 1% (33) | 23% | $952,466 |
| 2016 | 4,317 | 281 | 1% (45) | 24% | $914,974 |
| 2015 | 3,968 | 292 | 1% (42) | 26% | $635,041 |
| 2014 | 4,422 | 269 | 1% (30) | 26% | $703,487 |
| 2013 | 4,262 | 262 | 1% (31) | 31% | $610,689 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 48 drugs
| Sevelamer Carbonate | 148 | $98,923 | $668 |
| Jardiance | 78 | $80,271 | $1,029 |
| Velphoro | 23 | $76,114 | $3,309 |
| Veltassa | 36 | $38,086 | $1,058 |
| Rayaldee | 19 | $25,377 | $1,336 |
| Lokelma | 44 | $24,714 | $562 |
| Farxiga | 21 | $23,700 | $1,129 |
| Kerendia | 22 | $21,327 | $969 |
| Auryxia | 14 | $10,413 | $744 |
| Clinolipid | 39 | $8,130 | $208 |
| Losartan | 202 | $4,220 | $21 |
| Edarbi | 14 | $4,102 | $293 |
| Bumetanide | 46 | $3,265 | $71 |
| Metoprolol | 94 | $3,061 | $33 |
| Doxazosin Mesylate | 103 | $2,788 | $27 |
| Amlodipine Besylate | 247 | $2,649 | $11 |
| Calcium Acetate | 38 | $2,579 | $68 |
| Atorvastatin | 95 | $1,734 | $18 |
| Chlorthalidone | 49 | $1,701 | $35 |
| Telmisartan | 19 | $1,087 | $57 |
| Valsartan | 22 | $954 | $43 |
| Minoxidil | 23 | $909 | $40 |
| Furosemide | 88 | $874 | $10 |
| Mycophenolate Mofetil | 15 | $870 | $58 |
| Potassium Chloride | 27 | $750 | $28 |
| Lactulose | 28 | $685 | $24 |
| Pantoprazole | 28 | $670 | $24 |
| Hydralazine | 34 | $642 | $19 |
| Fluconazole | 19 | $607 | $32 |
| Carvedilol | 49 | $591 | $12 |
| Omeprazole | 32 | $544 | $17 |
| Torsemide | 28 | $540 | $19 |
| Allopurinol | 36 | $530 | $15 |
| Spironolactone | 18 | $443 | $25 |
| Ramipril | 23 | $360 | $16 |
| Lisinopril | 31 | $350 | $11 |
| Famotidine | 24 | $306 | $13 |
| Calcitriol | 20 | $281 | $14 |
| Glipizide | 20 | $281 | $14 |
| Prednisone | 22 | $223 | $10 |
| Levothyroxine | 16 | $208 | $13 |
| Metoprolol | 11 | $192 | $17 |
| Gabapentin | 24 | $189 | $8 |
| Tamsulosin | 12 | $178 | $15 |
| Ondansetron | 21 | $166 | $8 |
| Benazepril | 11 | $133 | $12 |
| Folic Acid | 22 | $52 | $2 |
| Vitamin D2 | 17 | $45 | $3 |
2022: 49 drugs
| Velphoro | 30 | $84,187 | $2,806 |
| Sevelamer Carbonate | 139 | $78,078 | $562 |
| Rayaldee | 44 | $52,759 | $1,199 |
| Jardiance | 74 | $49,254 | $666 |
| Veltassa | 41 | $41,583 | $1,014 |
| Lokelma | 63 | $30,870 | $490 |
| Lanthanum Carbonate | 18 | $10,641 | $591 |
| Farxiga | 12 | $10,341 | $862 |
| Auryxia | 15 | $9,072 | $605 |
| Invokana | 12 | $6,552 | $546 |
| Tacrolimus | 15 | $4,600 | $307 |
| Calcium Acetate | 69 | $4,492 | $65 |
| Procrit | 13 | $4,019 | $309 |
| Losartan | 283 | $3,871 | $14 |
| Valsartan | 33 | $3,078 | $93 |
| Retacrit | 11 | $3,069 | $279 |
| Metoprolol | 123 | $3,008 | $24 |
| Amlodipine Besylate | 289 | $2,314 | $8 |
| Bumetanide | 40 | $2,208 | $55 |
| Mycophenolate Mofetil | 20 | $2,157 | $108 |
| Chlorthalidone | 51 | $1,698 | $33 |
| Doxazosin Mesylate | 112 | $1,651 | $15 |
| Atorvastatin | 147 | $1,621 | $11 |
| Potassium Chloride | 44 | $1,131 | $26 |
| Lactulose | 26 | $1,100 | $42 |
| Fluconazole | 20 | $1,030 | $51 |
| Minoxidil | 32 | $925 | $29 |
| Ramipril | 31 | $911 | $29 |
| Furosemide | 108 | $868 | $8 |
| Hydralazine | 48 | $854 | $18 |
| Allopurinol | 47 | $794 | $17 |
| Carvedilol | 68 | $779 | $11 |
| Ondansetron | 17 | $509 | $30 |
| Torsemide | 18 | $500 | $28 |
| Ezetimibe | 17 | $462 | $27 |
| Tamsulosin | 13 | $409 | $31 |
| Pantoprazole | 39 | $391 | $10 |
| Spironolactone | 26 | $337 | $13 |
| Calcitriol | 16 | $309 | $19 |
| Omeprazole | 29 | $266 | $9 |
| Gabapentin | 33 | $263 | $8 |
| Famotidine | 25 | $231 | $9 |
| Lisinopril | 23 | $192 | $8 |
| Glipizide | 27 | $141 | $5 |
| Vitamin D2 | 18 | $127 | $7 |
| Prednisone | 27 | $125 | $5 |
| Pioglitazone | 17 | $116 | $7 |
| Clopidogrel | 11 | $113 | $10 |
| Metoprolol | 21 | $70 | $3 |
2021: 53 drugs
| Velphoro | 33 | $89,787 | $2,721 |
| Sevelamer Carbonate | 158 | $64,392 | $408 |
| Renvela | 29 | $55,427 | $1,911 |
| Auryxia | 59 | $47,418 | $804 |
| Veltassa | 44 | $42,477 | $965 |
| Lokelma | 94 | $30,095 | $320 |
| Jardiance | 29 | $21,223 | $732 |
| Rayaldee | 16 | $18,845 | $1,178 |
| Invokana | 16 | $8,839 | $552 |
| Calcium Acetate | 88 | $8,457 | $96 |
| Tacrolimus | 16 | $5,333 | $333 |
| Metoprolol | 134 | $3,215 | $24 |
| Losartan | 254 | $3,089 | $12 |
| Bumetanide | 11 | $2,991 | $272 |
| Doxazosin Mesylate | 128 | $2,070 | $16 |
| Atorvastatin | 183 | $1,921 | $10 |
| Potassium Chloride | 51 | $1,518 | $30 |
| Amlodipine Besylate | 236 | $1,463 | $6 |
| Midodrine | 13 | $1,406 | $108 |
| Chlorthalidone | 30 | $1,274 | $42 |
| Paricalcitol | 11 | $1,239 | $113 |
| Mycophenolate Mofetil | 12 | $1,222 | $102 |
| Allopurinol | 68 | $1,182 | $17 |
| Carvedilol | 105 | $1,018 | $10 |
| Ramipril | 55 | $1,001 | $18 |
| Diltiazem 24hr Er | 21 | $794 | $38 |
| Minoxidil | 23 | $746 | $32 |
| Furosemide | 99 | $724 | $7 |
| Hydralazine | 40 | $720 | $18 |
| Torsemide | 34 | $653 | $19 |
| Ondansetron | 13 | $621 | $48 |
| Loperamide | 17 | $585 | $34 |
| Spironolactone | 24 | $556 | $23 |
| Lactulose | 33 | $458 | $14 |
| Omeprazole | 39 | $453 | $12 |
| Fluconazole | 13 | $452 | $35 |
| Nifedipine Er | 16 | $393 | $25 |
| Calcitriol | 20 | $374 | $19 |
| Ezetimibe | 15 | $292 | $19 |
| Gabapentin | 40 | $236 | $6 |
| Lisinopril | 35 | $233 | $7 |
| Atenolol | 13 | $230 | $18 |
| Lidocaine-Prilocaine | 11 | $227 | $21 |
| Terazosin | 17 | $217 | $13 |
| Pantoprazole | 18 | $199 | $11 |
| Glipizide | 34 | $171 | $5 |
| Ropinirole | 15 | $153 | $10 |
| Prednisone | 27 | $136 | $5 |
| Famotidine | 18 | $121 | $7 |
| Levothyroxine | 11 | $108 | $10 |
| Metoprolol | 20 | $106 | $5 |
| Clopidogrel | 15 | $79 | $5 |
| Pioglitazone | 15 | $68 | $5 |
2020: 53 drugs
| Renvela | 60 | $117,322 | $1,955 |
| Velphoro | 41 | $85,749 | $2,091 |
| Sevelamer Carbonate | 139 | $55,851 | $402 |
| Auryxia | 63 | $55,032 | $874 |
| Veltassa | 29 | $24,860 | $857 |
| Lokelma | 51 | $13,420 | $263 |
| Levemir Flextouch | 11 | $11,929 | $1,084 |
| Jardiance | 14 | $6,760 | $483 |
| Calcium Acetate | 72 | $5,903 | $82 |
| Midodrine | 16 | $5,183 | $324 |
| Metoprolol | 118 | $2,546 | $22 |
| Tacrolimus | 16 | $2,357 | $147 |
| Potassium Chloride | 88 | $2,234 | $25 |
| Losartan | 192 | $1,973 | $10 |
| Chlorthalidone | 39 | $1,558 | $40 |
| Paricalcitol | 14 | $1,507 | $108 |
| Diltiazem 24hr Er (Cd) | 11 | $1,447 | $132 |
| Febuxostat | 11 | $1,385 | $126 |
| Atorvastatin | 160 | $1,358 | $8 |
| Clonidine | 12 | $1,350 | $113 |
| Amlodipine Besylate | 266 | $1,260 | $5 |
| Doxazosin Mesylate | 85 | $1,257 | $15 |
| Mycophenolate Mofetil | 18 | $1,168 | $65 |
| Telmisartan | 11 | $1,039 | $94 |
| Furosemide | 155 | $973 | $6 |
| Hydralazine | 61 | $829 | $14 |
| Allopurinol | 48 | $775 | $16 |
| Minoxidil | 29 | $712 | $25 |
| Lactulose | 24 | $678 | $28 |
| Ramipril | 36 | $670 | $19 |
| Calcitriol | 33 | $620 | $19 |
| Torsemide | 34 | $583 | $17 |
| Carvedilol | 90 | $582 | $6 |
| Diltiazem 24hr Er | 17 | $558 | $33 |
| Valsartan | 11 | $549 | $50 |
| Omeprazole | 37 | $542 | $15 |
| Ezetimibe | 20 | $420 | $21 |
| Fluconazole | 13 | $410 | $32 |
| Isosorbide Mononitrate Er | 19 | $330 | $17 |
| Gabapentin | 49 | $310 | $6 |
| Lidocaine-Prilocaine | 12 | $282 | $24 |
| Lisinopril | 50 | $260 | $5 |
| Levothyroxine | 21 | $256 | $12 |
| Prednisone | 29 | $160 | $6 |
| Tamsulosin | 14 | $146 | $10 |
| Pantoprazole | 18 | $133 | $7 |
| Spironolactone | 15 | $122 | $8 |
| Benazepril | 12 | $102 | $8 |
| Glipizide | 19 | $101 | $5 |
| Metoprolol | 17 | $84 | $5 |
| Clopidogrel | 15 | $68 | $5 |
| Pioglitazone | 11 | $45 | $4 |
| Cephalexin | 11 | $41 | $4 |
2019: 55 drugs
| Renvela | 92 | $122,299 | $1,329 |
| Auryxia | 88 | $78,198 | $889 |
| Sevelamer Carbonate | 182 | $74,363 | $409 |
| Velphoro | 33 | $73,103 | $2,215 |
| Veltassa | 41 | $34,520 | $842 |
| Calcium Acetate | 87 | $6,891 | $79 |
| Advair Diskus | 11 | $4,389 | $399 |
| Metoprolol | 125 | $3,895 | $31 |
| Midodrine | 20 | $3,733 | $187 |
| Bumetanide | 22 | $2,825 | $128 |
| Paricalcitol | 38 | $2,589 | $68 |
| Atorvastatin | 199 | $2,019 | $10 |
| Amlodipine Besylate | 316 | $2,000 | $6 |
| Doxazosin Mesylate | 78 | $1,921 | $25 |
| Losartan | 221 | $1,743 | $8 |
| Ventolin Hfa | 18 | $1,462 | $81 |
| Potassium Chloride | 42 | $1,439 | $34 |
| Clonidine | 11 | $1,292 | $117 |
| Chlorthalidone | 50 | $1,292 | $26 |
| Allopurinol | 52 | $1,103 | $21 |
| Minoxidil | 42 | $1,101 | $26 |
| Omeprazole | 70 | $1,027 | $15 |
| Diltiazem 24hr Er (Cd) | 11 | $1,023 | $93 |
| Hydralazine | 77 | $934 | $12 |
| Carvedilol | 105 | $925 | $9 |
| Furosemide | 160 | $920 | $6 |
| Ramipril | 49 | $841 | $17 |
| Valsartan | 12 | $617 | $51 |
| Torsemide | 43 | $566 | $13 |
| Colcrys | 12 | $565 | $47 |
| Mycophenolate Mofetil | 12 | $546 | $46 |
| Ezetimibe | 12 | $518 | $43 |
| Diltiazem 24hr Er | 14 | $511 | $37 |
| Lactulose | 30 | $499 | $17 |
| Nifedipine Er | 17 | $446 | $26 |
| Calcitriol | 29 | $437 | $15 |
| Gabapentin | 80 | $429 | $5 |
| Pravastatin | 12 | $348 | $29 |
| Levothyroxine | 20 | $286 | $14 |
| Lidocaine-Prilocaine | 13 | $282 | $22 |
| Clonidine | 21 | $266 | $13 |
| Pantoprazole | 26 | $207 | $8 |
| Clopidogrel | 34 | $199 | $6 |
| Benazepril | 26 | $198 | $8 |
| Lisinopril | 44 | $185 | $4 |
| Tamsulosin | 13 | $165 | $13 |
| Isosorbide Mononitrate Er | 14 | $162 | $12 |
| Metoprolol | 23 | $150 | $7 |
| Atenolol | 28 | $123 | $4 |
| Glipizide | 27 | $98 | $4 |
| Cyclobenzaprine | 12 | $82 | $7 |
| Famotidine | 12 | $58 | $5 |
| Prednisone | 13 | $50 | $4 |
| Metformin | 12 | $47 | $4 |
| Sertraline | 12 | $38 | $3 |
2018: 58 drugs
| Renvela | 234 | $258,296 | $1,104 |
| Sevelamer Carbonate | 129 | $69,949 | $542 |
| Veltassa | 32 | $24,389 | $762 |
| Lanthanum Carbonate | 19 | $23,463 | $1,235 |
| Sensipar | 23 | $22,469 | $977 |
| Renagel | 16 | $19,768 | $1,236 |
| Auryxia | 23 | $14,638 | $636 |
| Calcium Acetate | 123 | $8,407 | $68 |
| Metoprolol | 205 | $6,505 | $32 |
| Mesalamine | 12 | $6,497 | $541 |
| Tacrolimus | 12 | $5,124 | $427 |
| Doxazosin Mesylate | 167 | $3,075 | $18 |
| Paricalcitol | 27 | $2,637 | $98 |
| Bumetanide | 13 | $2,627 | $202 |
| Atorvastatin | 258 | $2,097 | $8 |
| Midodrine | 28 | $1,973 | $70 |
| Amlodipine Besylate | 335 | $1,468 | $4 |
| Losartan | 234 | $1,422 | $6 |
| Chlorthalidone | 46 | $1,369 | $30 |
| Ezetimibe | 23 | $1,289 | $56 |
| Ventolin Hfa | 22 | $1,208 | $55 |
| Allopurinol | 73 | $1,072 | $15 |
| Hydralazine | 80 | $1,009 | $13 |
| Omeprazole | 127 | $971 | $8 |
| Minoxidil | 57 | $963 | $17 |
| Mycophenolate Mofetil | 18 | $917 | $51 |
| Ramipril | 58 | $777 | $13 |
| Insulin | 17 | $730 | $43 |
| Metolazone | 16 | $720 | $45 |
| Potassium Chloride | 41 | $699 | $17 |
| Calcitriol | 41 | $682 | $17 |
| Lactulose | 47 | $664 | $14 |
| Furosemide | 136 | $658 | $5 |
| Nifedipine Er | 22 | $642 | $29 |
| Carvedilol | 108 | $581 | $5 |
| Levothyroxine | 42 | $561 | $13 |
| Torsemide | 60 | $548 | $9 |
| Valsartan | 12 | $529 | $44 |
| Gabapentin | 88 | $475 | $5 |
| Nystop | 13 | $405 | $31 |
| Pantoprazole | 46 | $324 | $7 |
| Tamsulosin | 20 | $254 | $13 |
| Clopidogrel | 41 | $223 | $5 |
| Lisinopril | 75 | $211 | $3 |
| Prednisone | 36 | $196 | $5 |
| Glipizide Er | 16 | $158 | $10 |
| Promethazine | 24 | $155 | $6 |
| Clonidine | 29 | $155 | $5 |
| Dutasteride | 11 | $143 | $13 |
| Benazepril | 27 | $137 | $5 |
| Metoprolol | 39 | $129 | $3 |
| Isosorbide Mononitrate Er | 12 | $104 | $9 |
| Glipizide | 34 | $102 | $3 |
| Ropinirole | 13 | $100 | $8 |
| Paroxetine | 15 | $84 | $6 |
| Cephalexin | 18 | $72 | $4 |
| Cyclobenzaprine | 11 | $72 | $7 |
| Metformin | 12 | $52 | $4 |
2017: 68 drugs
| Renvela | 372 | $454,146 | $1,221 |
| Sensipar | 179 | $257,880 | $1,441 |
| Fosrenol | 28 | $42,204 | $1,507 |
| Veltassa | 26 | $16,510 | $635 |
| Lantus | 53 | $16,195 | $306 |
| Sevelamer Carbonate | 11 | $14,172 | $1,288 |
| Calcium Acetate | 116 | $9,144 | $79 |
| Novolog | 31 | $8,616 | $278 |
| Metoprolol | 209 | $6,655 | $32 |
| Zetia | 15 | $6,611 | $441 |
| Paricalcitol | 28 | $4,419 | $158 |
| Atorvastatin | 297 | $2,409 | $8 |
| Doxazosin Mesylate | 101 | $2,110 | $21 |
| Midodrine | 24 | $1,881 | $78 |
| Omega-3 Acid Ethyl Esters | 16 | $1,810 | $113 |
| Amlodipine Besylate | 412 | $1,754 | $4 |
| Losartan | 213 | $1,691 | $8 |
| Hydralazine | 125 | $1,618 | $13 |
| Metolazone | 23 | $1,585 | $69 |
| Diltiazem 24hr Er | 20 | $1,532 | $77 |
| Mycophenolate Mofetil | 19 | $1,484 | $78 |
| Levothyroxine | 93 | $1,227 | $13 |
| Lidocaine-Prilocaine | 31 | $1,120 | $36 |
| Valsartan | 36 | $1,115 | $31 |
| Calcitriol | 58 | $1,102 | $19 |
| Allopurinol | 74 | $1,098 | $15 |
| Chlorthalidone | 28 | $979 | $35 |
| Fluconazole | 13 | $967 | $74 |
| Ramipril | 116 | $921 | $8 |
| Pravastatin | 38 | $892 | $23 |
| Minoxidil | 57 | $888 | $16 |
| Carvedilol | 132 | $866 | $7 |
| Omeprazole | 125 | $837 | $7 |
| Potassium Chloride | 47 | $834 | $18 |
| Torsemide | 84 | $794 | $9 |
| Lactulose | 47 | $787 | $17 |
| Insulin | 12 | $763 | $64 |
| Furosemide | 147 | $760 | $5 |
| Nifedipine Er | 18 | $648 | $36 |
| Nystop | 11 | $620 | $56 |
| Proair Hfa | 11 | $617 | $56 |
| Ultra-Fine Nano Pen Needle | 14 | $599 | $43 |
| Gabapentin | 101 | $514 | $5 |
| Prednisone | 59 | $487 | $8 |
| Polyethylene Glycol 3350 | 13 | $333 | $26 |
| Tamsulosin | 24 | $302 | $13 |
| Warfarin | 18 | $296 | $16 |
| Pantoprazole | 35 | $225 | $6 |
| Lisinopril | 78 | $213 | $3 |
| Clonidine | 25 | $200 | $8 |
| Megestrol Acetate | 11 | $199 | $18 |
| Paroxetine | 29 | $197 | $7 |
| Amiodarone | 21 | $196 | $9 |
| Glipizide Er | 21 | $185 | $9 |
| Hydrocodone-Acetaminophen | 13 | $166 | $13 |
| Simvastatin | 27 | $156 | $6 |
| Metoprolol | 41 | $136 | $3 |
| Benazepril | 23 | $107 | $5 |
| Atenolol | 22 | $102 | $5 |
| Metoclopramide | 14 | $100 | $7 |
| Ropinirole | 16 | $90 | $6 |
| Clopidogrel | 16 | $87 | $5 |
| Hydrochlorothiazide | 22 | $85 | $4 |
| Glipizide | 26 | $76 | $3 |
| Cyclobenzaprine | 12 | $64 | $5 |
| Tramadol | 18 | $64 | $4 |
| Metformin | 12 | $54 | $5 |
| Fluoxetine | 18 | $33 | $2 |
2016: 73 drugs
| Renvela | 326 | $456,105 | $1,399 |
| Sensipar | 137 | $177,093 | $1,293 |
| Fosrenol | 44 | $51,317 | $1,166 |
| Lantus | 54 | $17,821 | $330 |
| Veltassa | 21 | $11,641 | $554 |
| Zetia | 22 | $9,460 | $430 |
| Novolog | 36 | $9,080 | $252 |
| Calcium Acetate | 83 | $6,813 | $82 |
| Metoprolol | 182 | $6,551 | $36 |
| Paricalcitol | 29 | $6,115 | $211 |
| Omega-3 Acid Ethyl Esters | 32 | $4,855 | $152 |
| Tacrolimus | 11 | $4,331 | $394 |
| Nexium | 12 | $3,069 | $256 |
| Atorvastatin | 259 | $2,638 | $10 |
| Doxazosin Mesylate | 79 | $1,980 | $25 |
| Calcitriol | 70 | $1,912 | $27 |
| Hydralazine | 151 | $1,745 | $12 |
| Potassium Chloride | 81 | $1,591 | $20 |
| Mycophenolate Mofetil | 25 | $1,534 | $61 |
| Diltiazem 24hr Er | 18 | $1,501 | $83 |
| Chlorthalidone | 29 | $1,347 | $46 |
| Losartan | 170 | $1,330 | $8 |
| Amlodipine Besylate | 350 | $1,230 | $4 |
| Doxycycline Hyclate | 15 | $1,044 | $70 |
| Levothyroxine | 64 | $1,029 | $16 |
| Valsartan | 22 | $1,028 | $47 |
| Allopurinol | 74 | $985 | $13 |
| Ramipril | 130 | $883 | $7 |
| Fluconazole | 12 | $851 | $71 |
| Carvedilol | 148 | $849 | $6 |
| Pravastatin | 45 | $779 | $17 |
| Torsemide | 83 | $748 | $9 |
| Omeprazole | 115 | $732 | $6 |
| Ventolin Hfa | 14 | $729 | $52 |
| Midodrine | 13 | $693 | $53 |
| Amlodipine Besylate-Benazepril | 20 | $682 | $34 |
| Furosemide | 127 | $667 | $5 |
| Lidocaine-Prilocaine | 17 | $497 | $29 |
| Gentamicin Sulfate | 11 | $481 | $44 |
| Hydrocodone-Acetaminophen | 23 | $461 | $20 |
| Phenytoin Sodium Extended | 11 | $414 | $38 |
| Polyethylene Glycol 3350 | 22 | $411 | $19 |
| Lactulose | 36 | $343 | $10 |
| Prednisone | 42 | $336 | $8 |
| Insulin | 11 | $321 | $29 |
| Minoxidil | 16 | $289 | $18 |
| Metoprolol | 66 | $263 | $4 |
| Lisinopril | 70 | $258 | $4 |
| Gabapentin | 68 | $250 | $4 |
| Ropinirole | 14 | $225 | $16 |
| Atenolol | 34 | $211 | $6 |
| Labetalol | 11 | $196 | $18 |
| Isosorbide Mononitrate Er | 11 | $189 | $17 |
| Simvastatin | 31 | $189 | $6 |
| Benazepril | 35 | $187 | $5 |
| Pantoprazole | 25 | $174 | $7 |
| Nifedipine Er | 12 | $174 | $14 |
| Fluticasone Propionate | 12 | $151 | $13 |
| Prochlorperazine Maleate | 16 | $150 | $9 |
| Amitriptyline | 15 | $146 | $10 |
| Levofloxacin | 11 | $146 | $13 |
| Levetiracetam | 11 | $131 | $12 |
| Paroxetine | 14 | $127 | $9 |
| Hydrochlorothiazide | 24 | $103 | $4 |
| Glipizide | 27 | $98 | $4 |
| Clopidogrel | 12 | $93 | $8 |
| Amiodarone | 18 | $88 | $5 |
| Metoclopramide | 16 | $83 | $5 |
| Glipizide Xl | 12 | $82 | $7 |
| Escitalopram | 13 | $68 | $5 |
| Tramadol | 20 | $66 | $3 |
| Fluoxetine | 15 | $46 | $3 |
| Cyclobenzaprine | 11 | $23 | $2 |
2015: 62 drugs
| Renvela | 269 | $336,781 | $1,252 |
| Sensipar | 105 | $114,004 | $1,086 |
| Fosrenol | 50 | $31,604 | $632 |
| Lantus | 39 | $10,856 | $278 |
| Calcium Acetate | 109 | $9,164 | $84 |
| Coreg Cr | 16 | $8,749 | $547 |
| Metoprolol | 208 | $7,500 | $36 |
| Omega-3 Acid Ethyl Esters | 37 | $6,554 | $177 |
| Paricalcitol | 22 | $6,114 | $278 |
| Zetia | 14 | $5,137 | $367 |
| Novolog | 21 | $4,594 | $219 |
| Atorvastatin | 189 | $2,580 | $14 |
| Dexilant | 11 | $2,331 | $212 |
| Doxazosin Mesylate | 98 | $2,245 | $23 |
| Novolin R | 15 | $2,175 | $145 |
| Calcitriol | 64 | $1,943 | $30 |
| Hydralazine | 122 | $1,897 | $16 |
| Mycophenolate Mofetil | 19 | $1,789 | $94 |
| Amlodipine Besylate | 402 | $1,703 | $4 |
| Doxycycline Hyclate | 14 | $1,569 | $112 |
| Chlorthalidone | 34 | $1,223 | $36 |
| Fenofibric Acid | 11 | $1,141 | $104 |
| Losartan | 168 | $1,128 | $7 |
| Valsartan | 12 | $1,076 | $90 |
| Ramipril | 109 | $1,037 | $10 |
| Fenofibrate | 12 | $984 | $82 |
| Omeprazole | 157 | $971 | $6 |
| Torsemide | 80 | $883 | $11 |
| Fluconazole | 12 | $865 | $72 |
| Carvedilol | 148 | $860 | $6 |
| Potassium Chloride | 47 | $782 | $17 |
| Levothyroxine | 62 | $772 | $12 |
| Furosemide | 95 | $693 | $7 |
| Allopurinol | 48 | $634 | $13 |
| Amlodipine Besylate-Benazepril | 18 | $597 | $33 |
| Pravastatin | 24 | $593 | $25 |
| Hydrocodone-Acetaminophen | 21 | $469 | $22 |
| Nifedipine Er | 19 | $461 | $24 |
| Prednisone | 34 | $364 | $11 |
| Metoprolol | 90 | $349 | $4 |
| Pioglitazone | 15 | $309 | $21 |
| Lisinopril | 84 | $304 | $4 |
| Pantoprazole | 34 | $278 | $8 |
| Benazepril | 46 | $275 | $6 |
| Isosorbide Mononitrate Er | 15 | $235 | $16 |
| Simvastatin | 49 | $221 | $5 |
| Gabapentin | 35 | $209 | $6 |
| Fluticasone Propionate | 15 | $200 | $13 |
| Lactulose | 19 | $193 | $10 |
| Insulin | 14 | $191 | $14 |
| Minoxidil | 15 | $161 | $11 |
| Glipizide | 33 | $151 | $5 |
| Amitriptyline | 13 | $142 | $11 |
| Constulose | 11 | $138 | $13 |
| Clonidine | 14 | $126 | $9 |
| Atenolol | 33 | $116 | $4 |
| Hydrochlorothiazide | 27 | $87 | $3 |
| Tramadol | 21 | $62 | $3 |
| Cephalexin | 13 | $53 | $4 |
| Metoclopramide | 15 | $53 | $4 |
| Alprazolam | 15 | $29 | $2 |
| Citalopram Hbr | 11 | $23 | $2 |
2014: 64 drugs
| Renvela | 315 | $343,378 | $1,090 |
| Sensipar | 119 | $129,084 | $1,085 |
| Fosrenol | 40 | $43,379 | $1,084 |
| Paricalcitol | 48 | $13,816 | $288 |
| Lantus | 55 | $13,358 | $243 |
| Calcium Acetate | 109 | $11,690 | $107 |
| Lovaza | 49 | $10,324 | $211 |
| Diovan | 38 | $8,791 | $231 |
| Coreg Cr | 17 | $7,599 | $447 |
| Metoprolol | 184 | $6,173 | $34 |
| Uloric | 13 | $5,015 | $386 |
| Colcrys | 21 | $3,992 | $190 |
| Novolog | 20 | $3,739 | $187 |
| Calcitriol | 64 | $2,976 | $46 |
| Atorvastatin | 205 | $2,962 | $14 |
| Hydralazine | 111 | $2,685 | $24 |
| Exforge | 12 | $2,587 | $216 |
| Doxazosin Mesylate | 100 | $2,420 | $24 |
| Mycophenolate Mofetil | 24 | $2,390 | $100 |
| Omega-3 Acid Ethyl Esters | 12 | $2,172 | $181 |
| Amlodipine Besylate | 424 | $2,116 | $5 |
| Fenofibric Acid | 14 | $1,869 | $134 |
| Torsemide | 126 | $1,719 | $14 |
| Fenofibrate | 15 | $1,439 | $96 |
| Amlodipine Besylate-Benazepril | 25 | $1,328 | $53 |
| Pravastatin | 57 | $1,305 | $23 |
| Novolin R | 12 | $1,296 | $108 |
| Omeprazole | 155 | $1,260 | $8 |
| Ramipril | 114 | $1,166 | $10 |
| Carvedilol | 139 | $1,101 | $8 |
| Pioglitazone | 25 | $1,030 | $41 |
| Losartan | 125 | $990 | $8 |
| Levothyroxine | 71 | $917 | $13 |
| Furosemide | 123 | $841 | $7 |
| Chlorthalidone | 31 | $821 | $26 |
| Metoprolol | 158 | $768 | $5 |
| Nifedipine Er | 19 | $621 | $33 |
| Allopurinol | 98 | $612 | $6 |
| Lisinopril | 110 | $559 | $5 |
| Diltiazem 24hr Cd | 16 | $484 | $30 |
| Hydrocodone-Acetaminophen | 25 | $477 | $19 |
| Simvastatin | 75 | $460 | $6 |
| Felodipine Er | 23 | $411 | $18 |
| Benazepril | 58 | $372 | $6 |
| Clopidogrel | 13 | $364 | $28 |
| Potassium Chloride | 21 | $344 | $16 |
| Gabapentin | 53 | $316 | $6 |
| Clonidine | 34 | $309 | $9 |
| Isosorbide Mononitrate Er | 17 | $306 | $18 |
| Klor-Con M20 | 21 | $275 | $13 |
| Atenolol | 57 | $265 | $5 |
| Prednisone | 31 | $261 | $8 |
| Minoxidil | 16 | $257 | $16 |
| Paroxetine | 27 | $233 | $9 |
| Levofloxacin | 12 | $211 | $18 |
| Lactulose | 17 | $188 | $11 |
| Glipizide | 29 | $146 | $5 |
| Amitriptyline | 17 | $122 | $7 |
| Hydrochlorothiazide | 28 | $107 | $4 |
| Pantoprazole | 15 | $102 | $7 |
| Metoclopramide | 18 | $92 | $5 |
| Famotidine | 13 | $90 | $7 |
| Spironolactone | 12 | $73 | $6 |
| Alprazolam | 17 | $66 | $4 |
2013: 71 drugs
| Renvela | 301 | $240,388 | $799 |
| Sensipar | 135 | $110,686 | $820 |
| Fosrenol | 32 | $33,122 | $1,035 |
| Zemplar | 58 | $23,720 | $409 |
| Diovan | 87 | $17,840 | $205 |
| Lantus | 61 | $10,209 | $167 |
| Lovaza | 46 | $8,835 | $192 |
| Tacrolimus | 11 | $8,054 | $732 |
| Crestor | 21 | $6,746 | $321 |
| Coreg Cr | 20 | $6,540 | $327 |
| Novolog | 26 | $6,105 | $235 |
| Paricalcitol | 14 | $5,933 | $424 |
| Clonidine | 20 | $5,764 | $288 |
| Calcium Acetate | 49 | $5,642 | $115 |
| Uloric | 18 | $5,642 | $313 |
| Atorvastatin | 189 | $4,160 | $22 |
| Zetia | 14 | $3,966 | $283 |
| Calcitriol | 58 | $3,727 | $64 |
| Metoprolol | 83 | $3,695 | $45 |
| Hydralazine | 102 | $3,046 | $30 |
| Pioglitazone | 31 | $2,786 | $90 |
| Amlodipine Besylate | 343 | $2,484 | $7 |
| Cymbalta | 12 | $2,464 | $205 |
| Mycophenolate Mofetil | 20 | $2,087 | $104 |
| Torsemide | 127 | $2,053 | $16 |
| Amlodipine Besylate-Benazepril | 37 | $1,968 | $53 |
| Ramipril | 113 | $1,920 | $17 |
| Losartan | 99 | $1,782 | $18 |
| Fenofibrate | 12 | $1,437 | $120 |
| Felodipine Er | 24 | $1,426 | $59 |
| Omeprazole | 112 | $1,317 | $12 |
| Carvedilol | 126 | $1,266 | $10 |
| Isosorbide Dinitrate | 17 | $1,226 | $72 |
| Metoprolol | 155 | $1,104 | $7 |
| Doxazosin Mesylate | 73 | $1,082 | $15 |
| Pravastatin | 67 | $1,077 | $16 |
| Furosemide | 134 | $984 | $7 |
| Potassium Chloride | 44 | $984 | $22 |
| Simvastatin | 97 | $786 | $8 |
| Diltiazem 24hr Cd | 18 | $731 | $41 |
| Chlorthalidone | 33 | $663 | $20 |
| Gabapentin | 73 | $610 | $8 |
| Allopurinol | 92 | $575 | $6 |
| Insulin | 21 | $524 | $25 |
| Lactulose | 31 | $523 | $17 |
| Metolazone | 11 | $509 | $46 |
| Lisinopril | 79 | $485 | $6 |
| Atenolol | 76 | $483 | $6 |
| Levothyroxine | 49 | $413 | $8 |
| Benazepril | 55 | $362 | $7 |
| Clonidine | 18 | $296 | $16 |
| Glipizide | 42 | $277 | $7 |
| Hydrocodone-Acetaminophen | 26 | $243 | $9 |
| Levofloxacin | 12 | $228 | $19 |
| Prednisone | 41 | $228 | $6 |
| Fluoxetine | 14 | $212 | $15 |
| Paroxetine | 17 | $210 | $12 |
| Minoxidil | 11 | $205 | $19 |
| Isosorbide Mononitrate Er | 16 | $192 | $12 |
| Klor-Con M20 | 12 | $192 | $16 |
| Metoclopramide | 28 | $183 | $7 |
| Folbee Plus | 11 | $163 | $15 |
| Spironolactone | 14 | $162 | $12 |
| Hydrochlorothiazide | 30 | $124 | $4 |
| Cephalexin | 16 | $116 | $7 |
| Famotidine | 15 | $107 | $7 |
| Amitriptyline | 27 | $102 | $4 |
| Enalapril Maleate | 11 | $98 | $9 |
| Vitamin D2 | 16 | $89 | $6 |
| Citalopram Hbr | 20 | $88 | $4 |
| Alprazolam | 11 | $50 | $5 |
Money from drug and device companies
$1,130 in 2025
| 2025 | 17 | 55 | None | $1,130 |
| 2024 | 13 | 57 | $2,550 | $6,004 |
| 2023 | 15 | 59 | None | $1,410 |
| 2022 | 13 | 100 | $16,744 | $24,079 |
| 2021 | 12 | 101 | $11,998 | $14,990 |
| 2020 | 11 | 82 | $6,150 | $7,374 |
| 2019 | 13 | 165 | $18,855 | $28,540 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Calliditas Therapeutics US | Tarpeyo | $243 | 20 payments
|
| Akebia Therapeutics | Vafseo | $189 | 4 payments
|
| Otsuka America Pharmaceutical | Jynarque | $138 | 5 payments
|
| Ardelyx | Ibsrela | $120 | 5 payments
|
| Novartis Pharmaceuticals | Fabhalta | $50 | 2 payments
|
| GlaxoSmithKline | Benlysta | $49 | 3 payments
|
See all 55 published payments
| Akebia Therapeutics | Meals · 2025-12-18 | Vafseo | $25 |
| Otsuka America Pharmaceutical | Meals · 2025-12-12 | Voyxact | $31 |
| Calliditas Therapeutics US | Meals · 2025-12-01 | Tarpeyo | $4 |
| Calliditas Therapeutics US | Meals · 2025-12-01 | Tarpeyo | $22 |
| Calliditas Therapeutics US | Meals · 2025-12-01 | Tarpeyo | $1 |
| Akebia Therapeutics | Meals · 2025-11-21 | Auryxia | $27 |
| Apellis Pharmaceuticals | Meals · 2025-11-18 | Empaveli | $19 |
| Novo Nordisk | Meals · 2025-11-08 | Wegovy | $19 |
| Calliditas Therapeutics US | Meals · 2025-11-03 | Tarpeyo | $2 |
| Calliditas Therapeutics US | Meals · 2025-11-03 | Tarpeyo | $25 |
| Calliditas Therapeutics US | Meals · 2025-10-21 | Tarpeyo | $1 |
| Calliditas Therapeutics US | Meals · 2025-10-21 | Tarpeyo | $28 |
| Ardelyx | Meals · 2025-09-30 | Ibsrela | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-29 | Kerendia | $27 |
| Novartis Pharmaceuticals | Meals · 2025-09-22 | Fabhalta | $23 |
| Calliditas Therapeutics US | Meals · 2025-09-17 | Tarpeyo | $17 |
| Akebia Therapeutics | Meals · 2025-09-17 | Vafseo | $113 |
| Calliditas Therapeutics US | Meals · 2025-09-11 | Tarpeyo | $2 |
| Calliditas Therapeutics US | Meals · 2025-09-11 | Tarpeyo | $7 |
| Calliditas Therapeutics US | Meals · 2025-09-11 | Tarpeyo | $22 |
| GlaxoSmithKline | Meals · 2025-09-05 | Benlysta | $15 |
| Otsuka America Pharmaceutical | Meals · 2025-08-28 | Jynarque | $28 |
| Amgen | Meals · 2025-08-04 | Evenity | $18 |
| Calliditas Therapeutics US | Meals · 2025-07-17 | Tarpeyo | $3 |
| Calliditas Therapeutics US | Meals · 2025-07-17 | Tarpeyo | $15 |
| Calliditas Therapeutics US | Meals · 2025-07-12 | Tarpeyo | $30 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-07-09 | Kerendia | $21 |
| Ardelyx | Meals · 2025-07-09 | Ibsrela | $24 |
| Novartis Pharmaceuticals | Meals · 2025-06-26 | Fabhalta | $27 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-25 | Jardiance | $24 |
| Calliditas Therapeutics US | Meals · 2025-06-25 | Tarpeyo | $1 |
| Calliditas Therapeutics US | Meals · 2025-06-25 | Tarpeyo | $15 |
| Otsuka America Pharmaceutical | Meals · 2025-06-20 | Jynarque | $28 |
| Novo Nordisk | Meals · 2025-06-17 | Ozempic | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-06-10 | Jynarque | $24 |
| Amgen | Meals · 2025-06-02 | Evenity | $20 |
| Kyowa Kirin | Meals · 2025-05-30 | Crysvita | $24 |
| Apellis Pharmaceuticals | Meals · 2025-05-16 | None | $17 |
| Ardelyx | Meals · 2025-05-07 | Ibsrela | $28 |
| ANI Pharmaceuticals | Meals · 2025-05-05 | Purified Cortrophin Gel | $21 |
| Akebia Therapeutics | Meals · 2025-04-22 | Vafseo | $23 |
| Mallinckrodt Hospital Products | Meals · 2025-04-21 | Acthar | $19 |
| Otsuka America Pharmaceutical | Meals · 2025-04-04 | Jynarque | $27 |
| Ardelyx | Meals · 2025-04-01 | Ibsrela | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-31 | Farxiga | $27 |
| Ardelyx | Meals · 2025-03-18 | Ibsrela | $23 |
| Calliditas Therapeutics US | Meals · 2025-03-08 | Tarpeyo | $3 |
| Calliditas Therapeutics US | Meals · 2025-03-07 | Tarpeyo | $30 |
| GlaxoSmithKline | Meals · 2025-02-28 | Benlysta | $19 |
| Fresenius USA Marketing | Meals · 2025-02-24 | Velphoro | $18 |
| Aurinia Pharma U.S. | Meals · 2025-02-21 | Lupkynis | $25 |
| Calliditas Therapeutics US | Meals · 2025-01-31 | Tarpeyo | $1 |
| Calliditas Therapeutics US | Meals · 2025-01-31 | Tarpeyo | $14 |
| Fresenius USA Marketing | Meals · 2025-01-22 | Velphoro | $20 |
| GlaxoSmithKline | Meals · 2025-01-15 | Benlysta | $16 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $6,004
| Akebia Therapeutics | Vafseo | $2,629 | 2 payments
|
| CSL Behring | None | $2,398 | 9 payments
|
| Travere Therapeutics | None | $184 | 2 payments
|
| Amgen | Aranesp | $182 | 8 payments
|
| Calliditas Therapeutics US | Tarpeyo | $136 | 14 payments
|
| Ardelyx | Ibsrela | $126 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $112 | 5 payments
|
| Fresenius USA Marketing | Velphoro | $97 | 5 payments
|
| Otsuka America Pharmaceutical | Jynarque | $45 | 2 payments
|
| Novo Nordisk | Ozempic | $29 | 2 payments
|
| GlaxoSmithKline | Jesduvroq | $24 | 1 payment
|
| Novartis Pharmaceuticals | None | $22 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $19 | 1 payment
|
2023: $1,410
| Travere Therapeutics | None | $328 | 6 payments
|
| Vifor Pharma | Veltassa | $253 | 18 payments
|
| Abbott Laboratories | Cardiomems | $150 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $116 | 4 payments
|
| GlaxoSmithKline | Benlysta | $103 | 6 payments
|
| Amgen | Tavneos | $98 | 4 payments
|
| Novartis Pharmaceuticals | Leqvio | $77 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $70 | 4 payments
|
| Fresenius USA Marketing | Velphoro | $53 | 5 payments
|
| OPKO Pharmaceuticals | Rayaldee | $44 | 2 payments
|
| Calliditas Therapeutics US | Tarpeyo | $44 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $20 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $19 | 1 payment
|
| Ardelyx | Ibsrela | $18 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $16 | 1 payment
|
2022: $24,079
| AstraZeneca Pharmaceuticals LP | Lokelma | $10,031 | 19 payments
|
| Vifor Pharma | Veltassa | $9,311 | 27 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $4,043 | 12 payments
|
| Fresenius USA Marketing | Velphoro | $220 | 14 payments
|
| OPKO Pharmaceuticals | Rayaldee | $158 | 12 payments
|
| Amgen | Parsabiv | $99 | 4 payments
|
| GlaxoSmithKline | Benlysta | $83 | 4 payments
|
| Akebia Therapeutics | Auryxia | $39 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $29 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $20 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $16 | 1 payment
|
| Kyowa Kirin | None | $16 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $15 | 1 payment
|
2021: $14,990
| Vifor Pharma | Veltassa | $5,714 | 23 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $5,615 | 13 payments
|
| Akebia Therapeutics | Auryxia | $1,579 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $1,463 | 26 payments
|
| Amgen | Parsabiv | $173 | 8 payments
|
| OPKO Pharmaceuticals | Rayaldee | $172 | 12 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $98 | 5 payments
|
| GlaxoSmithKline | Benlysta | $54 | 3 payments
|
| Aurinia Pharma U.S. | Lupkynis | $45 | 2 payments
|
| Horizon Therapeutics plc | Krystexxa | $42 | 2 payments
|
| Novartis Pharmaceuticals | Afinitor | $18 | 1 payment
|
| Abbott Laboratories | Cardiomems Hf System | $16 | 1 payment
|
2020: $7,374
| Relypsa | Veltassa | $4,427 | 33 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $2,340 | 10 payments
|
| Fresenius USA Marketing | Velphoro | $178 | 16 payments
|
| Amgen | Parsabiv | $134 | 6 payments
|
| Mallinckrodt Hospital Products | Acthar | $65 | 3 payments
|
| OPKO Pharmaceuticals | Rayaldee | $59 | 4 payments
|
| Otsuka America Pharmaceutical | Jynarque | $57 | 3 payments
|
| Alexion Pharmaceuticals | Soliris | $42 | 2 payments
|
| Horizon Therapeutics plc | Krystexxa | $38 | 2 payments
|
| AMAG Pharmaceuticals | Feraheme | $20 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $14 | 1 payment
|
2019: $28,540
| AstraZeneca Pharmaceuticals LP | Lokelma | $11,860 | 27 payments
|
| Relypsa | Veltassa | $8,465 | 63 payments
|
| Fresenius USA Marketing | Velphoro | $4,862 | 43 payments
|
| Akebia Therapeutics | Auryxia | $2,933 | 11 payments
|
| Amgen | Aranesp | $204 | 8 payments
|
| Otsuka America Pharmaceutical | Jynarque | $56 | 3 payments
|
| Janssen Pharmaceuticals | Invokana | $38 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $32 | 2 payments
|
| Covidien LP | Palindrome | $26 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $18 | 1 payment
|
| Shire North American Group | Natpara (Parathyroid Hormone) | $17 | 1 payment
|
| Daiichi Sankyo | Injectafer | $15 | 1 payment
|
| Hikma Pharmaceuticals USA | Mitigare | $14 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AKEBIA THERAPEUTICS INC · Akb-6548-Ci-0014 · 2019 | Their institution | $191,095 |
| AKEBIA THERAPEUTICS INC · Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) · 2020 | Their institution | $90,240 |
| Ardelyx, Inc. · Study To Evaluate the Use of Tenapanor As Core Therapy in the Treatment of Hyperphosphatemia (Optimize) · 2022 | Their institution | $81,585 |
| AKEBIA THERAPEUTICS INC · Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) · 2020 | Their institution | $71,926 |
| GlaxoSmithKline, LLC. · A 28-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Grou · 2019 | Their institution | $44,106 |
| GlaxoSmithKline, LLC. · A 28-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Grou · 2020 | Their institution | $43,268 |
| CSL Behring · A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study To Investigate the Efficacy and Safety of Csl300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis · 2025 | Their institution | $35,845 |
| AKEBIA THERAPEUTICS INC · Akb-6548-Ci-0014 · 2021 | Their institution | $29,256 |
| Janssen Research & Development, LLC · A Randomized Double Blind, Placebo Group, Two-Arm, Multicenter Study To Assess Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects With Type 2 Diabetes Mellitus and Nephropathy · 2019 | Their institution | $12,416 |
| AKEBIA THERAPEUTICS INC · Akb-6548-Ci-0015 · 2019 | Their institution | $11,715 |
| GlaxoSmithKline, LLC. · A 28-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Grou · 2021 | Their institution | $8,825 |
| AKEBIA THERAPEUTICS INC · Akb-6548-Ci-0015 · 2021 | Their institution | $6,594 |
| Aurinia Pharma U.S., Inc. · Lupkynis Registry Study · 2023 | Their institution | $6,250 |
| CSL Behring · A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study To Investigate the Efficacy and Safety of Csl300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis · 2024 | Their institution | $2,471 |
| AKEBIA THERAPEUTICS INC · Akb-Ci-6548-0015 · 2019 | Their institution | $493 |
| AKEBIA THERAPEUTICS INC · Akb-Ci-6548-0014 · 2019 | Their institution | $493 |
| Novartis Pharmaceuticals Corporation · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study To Evaluate the Efficacy and Safety of Lnp023 in Primary Iga Nephropathy Patients · 2022 | Their institution | $335 |
Professional record
- NPI
- 1073692083
- Licence
- CA A36123California A36123: Current · expires 2028-08-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA DOA361230
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X)
- Mailing address
- 917 Blanco Circle, Salinas, CA, 93901
- NPI first listed
- 2006-11-02
- NPI last updated
- 2025-04-17
- NPI record certified
- 2025-04-17
This is when the NPI record was last certified, not a medical board exam.